Table 2.
Baseline demographic and clinical characteristics of Study A participants by included vs not included in IPTW analysis
| a. Categorical measures: | ||||
|---|---|---|---|---|
| Not included (n=85) |
Included (n=438) |
|||
| Characteristic | Category | n (%) | n (%) | p value |
| Sex | Male | 41 (48.2%) | 217 (49.5%) | 0.8253 |
| Female | 44 (51.8%) | 221 (50.5%) | ||
| PKD genotype | NMD | 6 (15.4%) | 35 (8.0%) | 0.2528 |
| PKD1 | 28 (71.8%) | 327 (74.7%) | ||
| PKD2 | 5 (12.8%) | 76 (17.4%) | ||
| Treatment group | Lisinopril/Telmisartan | 38 (44.7%) | 217 (49.5%) | 0.4142 |
| Lisinopril/Placebo | 47 (55.3%) | 221 (50.5%) | ||
| Blood pressure group | Standard BP | 48 (56.5%) | 220 (50.2%) | 0.2920 |
| Low BP | 37 (43.5%) | 218 (49.8%) | ||
| b. Continuous measures: | |||||
|---|---|---|---|---|---|
| Not included (n=85) |
Included (n=438) |
||||
| Measure | n | Mean ± SD | n | Mean ± SD | p value |
| Age at baseline (years) | 85 | 35.4 ± 8.7 | 438 | 36.6 ± 8.3 | 0.2158 |
| BMI (kg/m2) | 75 | 25.8 ± 4.7 | 438 | 27.3 ± 5.2 | 0.0202 |
| Home average systolic BP (mmHg)* | 51 | 120.6 ± 9.4 | 438 | 121.2 ± 10.4 | 0.7095 |
| Home average diastolic BP (mmHg)* | 51 | 81.1 ± 7.1 | 438 | 80.7 ± 8.2 | 0.7641 |
| CKD EPI eGFR (mL/min/1.73 m2) | 84 | 94.5 ± 17.5 | 438 | 91.5 ± 17.6 | 0.1578 |
| Logarithm urine albumin (mg/24 hrs) | 69 | 3.3 ± 1.0 | 438 | 3.0 ± 0.9 | 0.0833 |
| Logarithm total kidney volume (mL) | 78 | 6.9 ± 0.6 | 438 | 7.0 ± 0.6 | 0.1569 |
| Left ventricular mass index (g/m2) | 68 | 64.9 ± 12.8 | 438 | 63.7 ± 13.2 | 0.5072 |
*
At the visit a participant first reported a home systolic and diastolic BP reading (for 96% of participants, this was at the baseline (71%) or 4 month (25%) visit)
BMI: body mass index; BP: blood pressure; CKD EPI eGFR: estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation; IPTW: inverse probability of treatment weighting; NMD: no mutation detected.